Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home...
April 01, 2026 06:24 ET | Source: Budpop

Best THCP Gummies in 2026: BudPop Ranked as the Leading THCP Gummy Brand for Potency and Flavor

BudPop earns top THCP gummy ranking in 2026 after independent reviewers tested 40+ brands on potency accuracy, lab verification, and ingredient quality.
March 31, 2026 18:48 ET | Source: Intermountain Health

Intermountain Health Primary Children’s Hospital Among First in the West to Join National Trauma & Grief Network

SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- INTERMOUNTAIN NEWS RELEASE Approximately 1 in 15 children in Utah will experience the death of a parent or sibling before the age of 18....
March 31, 2026 17:23 ET | Source: BCC Research LLC

Global Ion Exchange Materials Market to Reach $5.9 Billion by 2030, Driven by Green Hydrogen, Water Treatment Standards and Energy Security Demands

The study highlights expanding applications in water treatment, pharmaceuticals, and chemical processing as key drivers of global market growth.
March 31, 2026 17:22 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 20
March 31, 2026 16:20 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 31, 2026 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At...
March 31, 2026 15:44 ET | Source: Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.
March 31, 2026 13:35 ET | Source: healthinsurance.org

As graduation and tax season near, families reconsider keeping young adults on their health plans

Minneapolis, MN, March 31, 2026 (GLOBE NEWSWIRE) -- As tax filings are prepared and graduation season approaches, many families are taking a closer look at household finances, including health...
March 31, 2026 13:18 ET | Source: Indiana Rehabs

Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress

Indianapolis, INDIANA, March 31, 2026 (GLOBE NEWSWIRE) -- Indiana Rehabs has released its "State of Addiction in Indiana: Annual Report," revealing a remarkable 18% decline in overdose deaths in...